- Home
- EXAS vs MKTX Comparison
EXAS vs MKTX Comparison
Compare EXAS & MKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXAS
- MKTX
- Stock Information
- Founded
- EXAS 1995
- MKTX 2000
- Country
- EXAS United States
- MKTX United States
- Employees
- EXAS N/A
- MKTX N/A
- Industry
- EXAS Medical Specialities
- MKTX Investment Bankers/Brokers/Service
- Sector
- EXAS Health Care
- MKTX Finance
- Exchange
- EXAS Nasdaq
- MKTX Nasdaq
- Market Cap
- EXAS 12.3B
- MKTX 10.9B
- IPO Year
- EXAS N/A
- MKTX 2004
- Fundamental
- Price
- EXAS $71.05
- MKTX $293.97
- Analyst Decision
- EXAS Strong Buy
- MKTX Hold
- Analyst Count
- EXAS 13
- MKTX 11
- Target Price
- EXAS $79.00
- MKTX $252.64
- AVG Volume (30 Days)
- EXAS 1.4M
- MKTX 334.0K
- Earning Date
- EXAS 11-05-2024
- MKTX 11-06-2024
- Dividend Yield
- EXAS N/A
- MKTX 1.01%
- EPS Growth
- EXAS N/A
- MKTX 3.44
- EPS
- EXAS N/A
- MKTX 6.94
- Revenue
- EXAS $2,612,011,000.00
- MKTX $777,510,000.00
- Revenue This Year
- EXAS $15.53
- MKTX $9.79
- Revenue Next Year
- EXAS $13.78
- MKTX $10.39
- P/E Ratio
- EXAS N/A
- MKTX $41.61
- Revenue Growth
- EXAS 13.54
- MKTX 6.07
- 52 Week Low
- EXAS $40.62
- MKTX $192.42
- 52 Week High
- EXAS $79.62
- MKTX $297.97
- Technical
- Relative Strength Index (RSI)
- EXAS 55.81
- MKTX 73.59
- Support Level
- EXAS $68.61
- MKTX $287.30
- Resistance Level
- EXAS $71.49
- MKTX $292.08
- Average True Range (ATR)
- EXAS 1.91
- MKTX 4.93
- MACD
- EXAS -0.34
- MKTX -0.37
- Stochastic Oscillator
- EXAS 50.41
- MKTX 100.00
About EXAS Exact Sciences Corporation
Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a noninvasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, or MRD, colorectal cancer screening, and multicancer screening.
About MKTX MarketAxess Holdings Inc.
Founded in 2000, MarketAxess is a leading electronic fixed-income trading platform that connects broker/dealers and institutional investors. The company is primarily focused on credit based fixed income securities with its main trading products being US investment-grade and high-yield bonds, Eurobonds, and Emerging Market corporate debt. Recently the company has expanded more aggressively into Treasuries and municipal bonds with the acquisitions of LiquidityEdge and MuniBrokers in 2019 and 2021, respectively. The company also provides pre and post-trade services with its acquisition of Regulatory Reporting Hub from Deutsche Borse Group in 2020 adding to its product offerings.